Advertisement
News
Advertisement

Abiomed stock slumps on FDA setback

Fri, 12/07/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Abiomed Inc.’s (Nasdaq:ABMD) shares slid almost 6 percent Friday, before recovering slightly, after the medical device company announced the U.S. Food and Drug Administration will require the company to re-submit its already-approved miniature heart pump.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading